Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a first-of-its-kind study to improve outcomes for patients diagnosed with a rare disease known as Tuberous Sclerosis Complex (TSC). Surrogen, a subsidiary of Recombinetics Inc., is focused on d
November 2, 2020
· 3 min read